W
WeiGong Technology
Automated in-vitro diagnostic instruments and reagents
About WeiGong Technology
Shenzhen WeiGong Technology Ltd. is a high-tech enterprise specializing in the research, development, and industrialization of in-vitro diagnostic (IVD) instruments and reagents. The company was founded based on the National Overseas High-Level Talent Program. WeiGong Technology has received several awards, including being named one of the Top 300 Most Investable Enterprises in 2018, winning third place in the China Medical Device Innovation and Entrepreneurship Competition in 2019, and being listed in the Venture50 for HealthTech in 2022.
The company's core offerings include automated flow cytometry sample preparation systems, fluorescently labeled antibody reagents, and cytokine detection kits. One of its key products is the EasySampler, an automated device designed for clinical hospitals and disease control centers to handle the pre-analytical processing of various clinical blood and fluid samples for flow cytometry. The firm also developed EasyMagPlex fluorescence-coded beads, which feature high-purity magnetic separation. Its systems provide a fully automated workflow, from sample preparation and testing to analysis and reporting, aiming to enhance work efficiency and biosafety in clinical laboratories. The client base primarily consists of clinical laboratories, hospitals, and disease control centers.
WeiGong Technology operates through three subsidiaries: Shenzhen Wellgrow Biotechnology Ltd., which serves as the production base; Beijing Wellgrow Medical Technology Ltd., the R&D center; and Hunan Wellgrow Biotechnology Ltd. The research and development team includes professionals with extensive experience from companies like Beckman Coulter and Mindray, specializing in flow cytometry, hematology analyzers, and reagent development.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Headquarters
- Shenzhen, China
- Open positions
- None listed
- Dealroom signal
- 18.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jan 2022 | $28M | $110M | Cowin Capital · China Life Technology Innovation Fund · China Merchants Group | ↗ |
Growth signals
Latest recorded traffic for WeiGong Technology is 510 monthly website visits, down 48.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Cowin Capital- CFChina Life Technology Innovation Fund
China Merchants Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about WeiGong Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See WeiGong Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.